Nexalin Technology (NXL) Cash & Equivalents (2021 - 2026)

Nexalin Technology's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 94.19% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 94.19% increase from a year earlier, with the FY2025 full-year figure at $3.1 million, up 434.12% from the prior year.
• Cash & Equivalents retreated to $1.2 million in Q1 2026 per NXL's latest filing, from $3.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.9 million in Q3 2022 and bottomed at $162743.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $1.2 million (2026), against an average of $2.4 million.
• Biggest YoY gain for Cash & Equivalents was 434.12% in 2025; the steepest drop was 86.92% in 2025.
• Year by year, Cash & Equivalents stood at $162743.0 in 2022, then jumped by 256.53% to $580230.0 in 2023, then fell by 0.99% to $574485.0 in 2024, then surged by 434.12% to $3.1 million in 2025, then plunged by 60.63% to $1.2 million in 2026.
• Per Business Quant, the three latest NXL Cash & Equivalents figures stand at $1.2 million (Q1 2026), $3.1 million (Q4 2025), and $590075.0 (Q3 2025).